Session Details

AAV gene therapy has yielded promising results in preclinical animal models and clinical trials, with multiple AAV based therapies reaching regulatory approval. Yet, immune responses triggered by vector delivery remain a major limitation to the broader use of the technology. The session will cover the most current advances in the modulation of immune responses to AAV vectors. In particular, the topics covered will include novel approaches to immunomodulation, addressing acute toxicity in AAV gene transfer, strategies to evade humoral immunity to AAV, and tolerance induction to foreign proteins.